摘要
目的 :初步探讨多药耐药基因 1(mdr1)和 CD34 在急性白血病 (AL)中的表达及二者在多药耐药 (MDR)中的相关性。方法 :对 5 9例初发 AL患者治疗前及完全缓解 (CR)后 ,应用流式细胞仪 (FCM)测定 CD34 表达情况及半定量多聚酶链反应 (RT- PCR)测定 mdr1m RNA水平。结果 :m dr1、CD34 分别在急性髓性白血病 (AML)与急性淋巴细胞性白血病 (AL L)的表达无差异。mdr1+与 CD+ 34 呈正相关。COX回归分析 :AL 患者 CD34 、m dr1过度表达均对疗效有影响 ,而 m dr1表达更具判断预后价值。经 L og rank检验 ,mdr1+组与 mdrl-组、CD+ 34 组与 CD34 -组 CR率有显著性差异。结论 :mdrl和 CD34 均为 CR率低、疗效差、预后不良的重要因素。
Objective:To explore the role of mdrl and CD 34 expressions and their correlation in Acute Leukemia AL.Methods:We detected mdrl and CD 34from 59 newly AL patients before treatment and after CR with RT-PCR and FCM.Resultes:mdrl and CD 34expressions in AML and ALL had no difference.mdrl+ and CD+ 34had obviously positive correlation in ALL and AML.The resultes of COX regression models showed:mdrl and CD 34are prognositc factors,especially mdrl.Comparing the groups of mdrl+ with mdrl-,CD+ 34with CD- 34, we found that their CR rates had obvious difference.Conclusion:In AL,mdrl and CD 34expressions had highly correlation with the effect of treatment,both of them are important unfavorable factors.
出处
《临床医药实践》
2005年第2期93-95,共3页
Proceeding of Clinical Medicine
